Open AccessP897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T‐CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Author(s) -
Dalovisio A.,
Bahlis N.,
Raje N.,
Costello C.,
Dholaria B.,
Solh M.,
Levy M.,
Tomasson M.,
Dube H.,
Damore M.,
Jiang S.,
Basu C.,
Skoura A.,
Chan E.,
Trudel S.,
Jakubowiak A.,
Chu M.,
Gasparetto C.,
Sebag M.,
Lesokhin A.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846460.44039.3d
Subject(s) - medicine , multiple myeloma , cytokine release syndrome , adverse effect , common terminology criteria for adverse events , minimal residual disease , oncology , transplantation , immunology , gastroenterology , immunotherapy , cancer , chimeric antigen receptor , bone marrow